Standard BioTools (LAB) vs Treace Medical Concepts (TMCI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Treace Medical Concepts (TMCI) has outperformed Standard BioTools (LAB) over the past year, losing 35.2% versus a loss of 47.8%. Over five years, TMCI leads with a -84.1% price change compared with -87.3% for LAB. Standard BioTools is the larger company by market cap ($266.4 million vs $253.0 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | LAB | TMCI |
|---|---|---|
| Share price | $0.6787 | $3.89 |
| Market cap | $266.44M | $252.98M |
| 1-day change | -6.00% | -2.75% |
| YTD return | -46.98% | +58.78% |
| 1-year return | -47.79% | -35.17% |
| 5-year return | -87.29% | -84.07% |
| EPS (TTM) | $-0.13 | $-0.92 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $1.72 | $7.08 |
| 52-week low | $0.63 | $1.17 |
| Distance from 52-week high | -60.54% | -45.06% |
| Analyst consensus | none | none |
| Avg. price target upside | +98.91% | +41.39% |
| Average volume | 1.57M | 333.87K |
| Shares outstanding | 392.58M | 65.03M |
| Employees | 385 | 450 |
| Sector | Industrials | Health Care |
| Industry | Biotechnology: Laboratory Analytical Instruments | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- TMCI has outperformed LAB by 12.6 percentage points over the past year.
- The two companies sit in different sectors: Standard BioTools in Industrials and Treace Medical Concepts in Health Care.
About Standard BioTools
LAB stock →Standard BioTools Inc., together with its subsidiaries, develops, manufactures, and sells a range of instrumentation, consumables, and services to scientists and biomedical researchers to develop therapeutics in the Americas, Europe, the Middle East, Africa, and the Asia pacific. The company operates through Proteomics and Genomics segments.
Industrials · Biotechnology: Laboratory Analytical Instruments · 385 employees
About Treace Medical Concepts
TMCI stock →Treace Medical Concepts, Inc., a medical technology company, designs, manufactures, and markets medical devices in the United States. The company offers Lapiplasty System, enables surgeons to correct all three dimensions of the bunion deformity, stabilize the first TMT joint, and allow return to weight-bearing in a walking boot; minimally invasive products for four bunion classes; Nanoplasty 3D Minimally Invasive Bunion Correction System delivers a reproducible 3D correction of the bunion deformity through a cosmetically appealing; and Percuplasty Percutaneous 3D Bunion Correction System that provides 3D correction of the bunion deformity through percutaneous incisions.
Health Care · Medical/Dental Instruments · 450 employees
LAB vs TMCI FAQ
Which is bigger, Standard BioTools or Treace Medical Concepts?
Standard BioTools (LAB) is larger, with a market capitalization of $266.44M compared with $252.98M for Treace Medical Concepts (TMCI).
Which stock has performed better over the past year, LAB or TMCI?
TMCI returned -35.17% over the past 12 months, compared with -47.79% for LAB (price return, excluding dividends). Past performance does not predict future results.
Are Standard BioTools and Treace Medical Concepts in the same industry?
No. Standard BioTools is in the Industrials sector, while Treace Medical Concepts is in Health Care.